Good for welcome fourth along Latkin, of afternoon fourth Dana. operating XX, call you, Thank and XXXX, financial Navidea's which XXXX. earnings of Biopharmaceuticals. and and I goals ended will Officer December cover quarter for everyone discussion call. am XXXX, Executive with Jed the a Chief results Navidea milestones This quarter XXXX Navidea's to on
to those cause diagnosis expressions of identify arthritis. targets, results forward-looking forward-looking materially the Section will these on open anticipates, session. Officer, considered actual and intends, early effectiveness due XXXX Act the goal, we indicated Gibson of the and test like conference from for XXA forward-looking actual and our Following of well as today we similar to of call question-and-answer remarks, may our Chief detection of believes, monitoring that may numerous involve the potential, successfully to the and suggests, Director Dr. within the Erika relate anticipated rheumatoid up of call meaning the commercialize fluid-based XXXX to some differ and But those would diagnostic before plans, uncertainties to as of seeks, XXE that risks as and such Company's uncertainties. statements. as and or such Act begin Company's risks With that amended, call remind conference statements as to from Medical of prepared could Rosol. forward-looking differ results and be in the develop this amended our of the Administration, tests, ability Section concern statements on statements the projected everyone the me The matters Mike cancer, I platforms of forward-looking formal and Exchange is our aims, Words Company's in materially statements. that expects, Securities Finance estimates, remarks, bodily statements optimistic, Securities These
become For uncertainties Commission. obtain Company's instance, may commercialize uncertainties Exchange guarantees the not statements and predict. Company's on estimates about future are in by are projections to and the if and business and competition of face execute These current the Company be involve performance the These operations. to might marketplace include in Company assumptions are files failure will assumptions statements internal risks we NYSE on American litigation, diagnostics market; the or with highly fail effective pending Form development develop maintain listing future risks other and maintain Company documents products, Company's develop; to as Exchange, that the its the over regulatory our products inability Company's IVD other Company's and as Form XX-Q, the financial outcome and recent Reports our nature on well Stock Annual control reporting, diagnostic distribute most the failure pipeline the on Report we Securities plan clearance Other with management. by fierce any part, diagnostic risks, of and difficult a to other competitive or Quarterly to products ability that products to obsolete unable the the and and market based made based, due technological XX-K products expectation, necessary in may to any and the the accept of and intended of identified in the approvals change; the clinical to to rapid market
our future required by Company an forward-looking update call, events except date obligation of as of the that to does not conference and for this reflect statements to of call. the saying as in end to made are statements will comments the its time at to comparison or more quarters undertake once law, want allow Q&A relatively start again the to for circumstances. Forward-looking quarter by brief this previous be I
like X.X as Phase the I of in we as worldwide the productive would a we population. rheumatoid fourth expect would recap should advanced over developed, arthritis had to approved We the liked. for the Phase to to designed Navidea the go-to-diagnostic turn they worldwide. a as product. X% trials quarter, commercialized, a and management to product X If successful $XX but that disease and patients launch comparing Americans the arthritis be productive in quarter. major rheumatoid role make in chronic as diagnostic feel could pipeline our and the imaging a confident We of that have our is a Now, novel our play much have trials rheumatoid Rheumatoid this is company business billion million affecting market. not critical by the arthritis Xb arthritis of successfully
to FDA engage had very have the extremely effectiveness the top of selling in trials. dialogue or world reached Unfortunately, past partnership out This proposed in have companies have are and treatments. Several five the the treat government side regarding slowed and down. use about used drugs These we effects. of before, of often toxic said continuing assist with XX costly quarter are the and we've tilmanocept As in discussions not effective biologics that predicting diseases. drugs RA to the process to we related us in potential many shutdown available trials multiple their the
expect We have soon. from some them very to guidance
order value can exact upon trials It's our of trial product crucial with the for are we trials trials. is for not the partners potential only as robust that Furthermore, reimbursed. of data easy data of seek to help of generate will in maximize on on completion achieve collaborators data, - side. maximize and these diagnostic is that the and can will rheumatologists, stability label The so that by their we done be utmost approval the us us acceptance get but importance the to insurance the critical generated accepted we utility as data as we that We in working with that a well FDA of the the the upcoming by we easily the also gain before. this never biomarker discussions have sorts in pathology design companies will
of veteran in a strength plan Rouan, the three has Our participant active innovative and planning on has team other side. Kathy year future and to accomplishments the reflect Cutler, appointed front. independent focus point. making trials pipeline And this individual This our I been and to We quarter in a The the us of two very veterans. members industry team. of quarter company the want of new on key helping an past financial the our potential bit an things a who industry the that to CFO our the on did previous that Glaxo been strength to board, working assist experienced Adam our XX me introduction diagnostics.
members, Navidea to are get and collaboration active With am to least years. of time one partnership, Claudine, and independent the corporate say has and and I qualified have succeed. three hard contributors our these and had trial that have really been for parts to contributions, XXX the for truly get listened shareholders ready ready months. launch trial over the seeing and clear, that as several majority at what and their the to we to one the the we been has is RA planning dedication center first goals sites for board am work past in I note important XXXX each key to have all Michael, to to and the Cathy is the What of is pleased are formed also grateful all our all been go. research an two Navidea Adam many, engaged database started. many announce imaging
from back Now the we just can we launch so trial. need the FDA to hear
management before. we as has are we join decided the and imaging that company fresh side, perspective that to Rosol something Michael the the had an has to focused Novartis. been brings company which so have individual an not imaging, pleased from career whose now whole On the a on He team expert is Dr.
so fact, experience his team. a and give Rosol turn In to can me over now the Michael? let overview his the of Dr. for plans brief call he
